Angiogenesis in multiple myeloma

被引：138

作者：

Jakob, Christian ^{[1
]}

Sterz, Jan ^{[1
]}

Zavrski, Ivana ^{[1
]}

Heider, Ulrike ^{[1
]}

Kleeberg, Lorenz ^{[1
]}

Fleissner, Claudia ^{[1
]}

Kaiser, Martin ^{[1
]}

Sezer, Orhan ^{[1
]}

机构：

[1] Univ Med Berlin, Charite, Dept Haematol & Oncol, D-10117 Berlin, Germany

来源：

EUROPEAN JOURNAL OF CANCER | 2006年 / 42卷 / 11期

关键词：

multiple myeloma; angiogenesis; bone marrow; microenvironment; endothelial cells; cytokines; bFGF; VEGF; HGF;

D O I：

10.1016/j.ejca.2006.02.017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Multiple myeloma (MM) was the first haematological malignancy in which a prognostic relevance of bone marrow microvessel density (MVD) was shown. Myeloma-induced angiogenesis involves either the direct production of angiogenic molecules by myeloma cells or their induction in bone marrow stromal cells or endothelial cells (EC). Recent data demonstrate an increased angiogenic potential and a paracrine stimulatory effect of bone marrow EC on plasma cells (PC) in MM. Soluble angiogenic factors are elevated in bone marrow (BM) and in peripheral blood samples from myeloma patients. Furthermore, correlation with disease stage and prognosis was shown for serum levels of the angiogenic factors basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF). In this review we summarize recent data which give strong evidence for an increased angiogenic activity in bone marrow microenvironment and support the hypothesis that angiogenesis is not only an epiphenomenon of tumour growth but may also promote PC growth in MM. (c) 2006 Elsevier Ltd. All rights reserved.

引用

页码：1581 / 1590

页数：10

共 112 条

[61] Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease [J].

Kyrtsonis, MC ;

Vassilakopoulos, TP ;

Siakantaris, MP ;

Kokoris, SI ;

Gribabis, DA ;

Dimopoulou, MN ;

Angelopoulou, MK ;

Pangalis, GA .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2004, 72 (04) :252-258

[62]

Molina JR, 2003, HAEMATOLOGICA, V88, P122

[63] Expression and function of chemokine receptors in human multiple myeloma [J].

Möller, C ;

Strömberg, T ;

Juremalm, M ;

Nilsson, K ;

Nilsson, G .

LEUKEMIA, 2003, 17 (01) :203-210

[64] Evolving treatment strategies for myeloma [J].

Morgan, GJ ;

Davies, FE .

BRITISH JOURNAL OF CANCER, 2005, 92 (02) :217-221

[65] Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis [J].

Munshi, NC ;

Wilson, C .

SEMINARS IN ONCOLOGY, 2001, 28 (06) :565-569

[66] Tumor endothelial markers: new targets for cancer therapy [J].

Nanda, A ;

St Croix, B .

CURRENT OPINION IN ONCOLOGY, 2004, 16 (01) :44-49

[67]

Neben K, 2001, CLIN CANCER RES, V7, P2675

[68] Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III [J].

Niemöller, K ;

Jakob, C ;

Heider, U ;

Zavrski, I ;

Eucker, J ;

Kaufmann, O ;

Possinger, K ;

Sezer, O .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2003, 129 (04) :234-238

[69] Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells [J].

Pellegrino, A ;

Ria, R ;

Di Pietro, G ;

Cirulli, T ;

Surico, G ;

Pennisi, A ;

Morabito, F ;

Ribatti, D ;

Vacca, A .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 (02) :248-256

[70]

PerezAtayde AR, 1997, AM J PATHOL, V150, P815

← 2 3 4 5 6 7 8 9 10 11 →